Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine-Reference-Cited by-同舟云学术

Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine

Published:2023-02 Issue:7 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Lumish Melissa¹^ORCID,Thackray Jennifer²^ORCID,Do Richard Kinh Gian³^ORCID,Caudle Kelly E.⁴,Amstutz Ursula⁵^ORCID,Schwab Matthias⁶⁷⁸⁹^ORCID,Diasio Robert B.¹⁰^ORCID,Jarnagin William R.¹¹,Cercek Andrea¹^ORCID

Affiliation:

1. Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

2. Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY

3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

4. Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital Memphis, TN

5. Department of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland

6. Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

7. Department of Clinical Pharmacology, University Hospital, Tübingen, Germany

8. Departments of Clinical Pharmacology, and of Biochemistry and Pharmacy, University Hospital, Tübingen, Germany

9. Cluster of Excellence iFIT (EXC 2180), “Image-Guided and Functionally Instructed Tumor Therapies,” University of Tuebingen, Tuebingen, Germany

10. Department of Molecular Pharmacology and Experimental Therapeutics and Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN

11. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.22.00442

Reference32 articles.

1. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

2. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

3. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency

4. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Production of pyrimidine nucleosides in microbial systems via metabolic engineering: Theoretical analysis research and prospects;Biotechnology Advances;2024-10